Advances in our understanding of DNA, RNA and protein biomarkers have led to the development of genetic tests, molecular diagnostics and companion diagnostics that are changing our understanding and treatment of disease. Genetic testing can be used to:
- Screen for and diagnose disease
- Identify carriers for a genetic disease
- Determine if a patient has an inherited predisposition to a disease
As a healthcare professional, you can use the knowledge gained from genetic testing to educate your patients and take action to potentially reduce their risk of disease, diagnose it earlier or provide more informed and personalized treatment.
Myriad is a Leader in Genetic Testing, Molecular Diagnostics and Companion Diagnostics
More than 1.3 million patients have benefitted from Myriad’s BRACAnalysis®test, which was the first full-length gene sequencing test for a major, common disease and the standard of care for identifying individuals with hereditary breast and ovarian cancer.
Patients and their healthcare professionals trust Myriad to deliver what no other company can:
- More than 20 years of experience in hereditary cancer genetic testing
- 1,500,000+ patients tested
- 99.98%* analytic sensitivity
- 14 days or less for test turnaround time
- 97 percent of private insurance companies cover Myriad’s hereditary cancer genetic testing
At Myriad, we are committed to providing the highest-quality laboratory testing and delivering accurate, clinically actionable results to help you make better, more informed decisions. The Myriad myVision™ Variant Classification Program enables us to provide unmatched variant classification so that that your patient’s genetic testing results are as accurate as possible, reducing uncertainty for patients and their families, and increasing your confidence in providing treatment recommendations.
Learn more about our commitment to quality:
Genetic Testing for Hereditary Cancer Syndromes
Approximately five to 10 percent of all cancers are hereditary. Patients with a hereditary cancer are at a significant risk for developing an initial cancer and/or a second primary cancer. Hereditary cancer is more prevalent than might be expected. In fact, there are very likely patients in your practice who carry the genetic mutations responsible for increased cancer risk. Identifying these patients through appropriate testing can potentially lead to improved treatment options, more appropriate plans for risk management, and, ultimately, better outcomes.
On this site and MyriadPro.com, you will find comprehensive information on the most common hereditary cancer syndromes, and why inherited mutations in certain genes can lead to increased risk for breast, ovarian, colorectal, endometrial, gastric, prostate and pancreatic cancers and melanoma. You also will learn how to identify the familial patterns associated with hereditary cancer, and the appropriate processes for applying the powerful diagnostic tool of genetic testing.
*Based on internal validation data.